In particular, endogenous KYNA synthesized by glial cells is able to regulate the release of neurotransmitters such as dopaminergic and glutamatergic in the central nervous system by blocking α7nAChR and NMDA receptors, and thus it has unlimited potential for the treatment of neurodegenerative diseases [11,41]. Here, CHRNA7 is linked to neurodegenerative disease.